Triptorlin or Leuprorelin
DrugGonadotrophin releasing hormone agonists (GnRHa)
Other names: Triptorlin, Leuprorelin
NCT Number: NCT02920515
This is a prospective, multicentric, comparative, non-randomized interventional study in which subjects diagnosed with central precocious puberty (CPP) and early puberty (EP) were treated for 6 months to compare the effect with GnRHa and traditional Chinese medicines.
Looking for future studies?
Notify Me2 year–14 year
Female
Interventional
Phase 4
740 girls with CPP and EP participated in this study, all participates were divided into GnRHa group, traditional chinese medicines group and blank group. After at least six months therapy with GnRHa or traditional Chinese medicines, the investigators compare clinical parameters, sex hormone, bone age and ovarian ultrasound in three groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Gonadotrophin releasing hormone agonists (GnRHa)
Other names: Triptorlin, Leuprorelin
Traditional Chinese Medicine
Traditional Chinese Medicine
Time frame: 6 months
The change levels of height SDS in the GnRHa group (n=202) is lower than in the traditional chinese medicines group (n=155) ,(P<0.05).
Time frame: 6 months
The change levels of breast stages in the GnRHa group (n=181) is lower than in the traditional chinese medicines group (n=148) ,(P<0.05).
Time frame: 6 months
The change levels of BA/CA ratio in the GnRHa group (n=152) is lower than in the traditional chinese medicines group (n=86) ,(P<0.05).
Time frame: 6 months
The change levels of sex hormone(LH,FSH and E2) in the GnRHa group (n=164) is lower than in the traditional chinese medicines group (n=94) ,(P<0.05).
Time frame: 6 months
The change levels of uterine volume in the GnRHa group (n=157) is lower than in the traditional chinese medicines group (n=91) ,(P<0.05).
Time frame: 6 months
The change levels of ovarian volume in the GnRHa group (n=152) is lower than in the traditional chinese medicines group (n=88) ,(P<0.05).
Ruijin Hospital
Other
Multi-site Study of Comprehensive Treatment for Children Precocious Puberty
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05341128
Central Precocious Puberty, Endocrine System Diseases
Nanning, Guangxi, China
View Trial DetailsNCT05341115
Central Precocious Puberty, Endocrine System Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT05029622
Central Precocious Puberty, Endocrine System Diseases
Beijing, China
View Trial DetailsNCT04736602
Central Precocious Puberty, Endocrine System Diseases
Chengdu, China
View Trial Details